An open-label pilot study of icariin for co-morbid bipolar and alcohol use disorder

References

• Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511–2518.
   Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996;66:17–31.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007;64:543–552.
   PubMed Web of Science ®Google Scholar
• Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000;48:477–485.
   PubMed Web of Science ®Google Scholar
• Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry 2008;69:701–705.
   PubMed Web of Science ®Google Scholar
• Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res 2010;34:1822–1831.
   PubMed Web of Science ®Google Scholar
• Sherwood Brown E, Davila D, Nakamura A, Carmody TJ, Rush AJ, Lo A, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res 2014;38:2113–2118.
   PubMed Web of Science ®Google Scholar
• Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord 2012;14:54–63.
   PubMed Web of Science ®Google Scholar
• Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exper Res 2009;33:1863–1869.
   PubMed Web of Science ®Google Scholar
• Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005;62:37–45.
   PubMed Web of Science ®Google Scholar
• Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013;108:275–293.
   PubMed Web of Science ®Google Scholar
• Li C, Li Q, Mei Q, Lu T. Pharmacological effects and pharmacokinetic properties of icariin, the major bioactive component in Herba Epimedii. Life Sci 2015;126:57–68.
   PubMed Web of Science ®Google Scholar
• Liu B, Xu C, Wu X, Liu F, Du Y, Sun J, et al. Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation. Neuroscience 2015;294:193–205.
   PubMed Web of Science ®Google Scholar
• Pan Y, Kong L, Xia X, Zhang W, Xia Z, Jiang F. Antidepressant-like effect of icariin and its possible mechanism in mice. Pharmacol Biochem Behav 2005;82:686–694.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang H, Xu C, Yang G, Tao J, Huang J, et al. Neuroprotective effects of icariin on corticosterone-induced apoptosis in primary cultured rat hippocampal neurons. Brain Res 2011;1375:59–67.
   PubMed Web of Science ®Google Scholar
• Wu J, Du J, Xu C, Le J, Xu Y, Liu B, et al. Icariin attenuates social defeat-induced down-regulation of glucocorticoid receptor in mice. Pharmacol Biochem Behav 2011;98:273–278.
   PubMed Web of Science ®Google Scholar
• Jovicic MJ, Lukic I, Radojcic M, Adzic M, Maric NP. Modulation of c-Jun N-terminal kinase signaling and specific glucocorticoid receptor phosphorylation in the treatment of major depression. Med Hypotheses 2015;85:291–294.
   Google Scholar
• Aubry JM. CRF system and mood disorders. J Chem Neuroanat 2013;54:20–24.
   PubMed Web of Science ®Google Scholar
• Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther 2008;117:30–51.
   PubMed Web of Science ®Google Scholar
• Li F, Gong QH, Wu Q, Lu YF, Shi JS. Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacol Biochem Behav 2010;96:301–305.
   PubMed Web of Science ®Google Scholar
• Vicentic A, Jones DC. The CART (cocaine- and amphetamine-regulated transcript) system in appetite and drug addiction. J Pharmacol Exp Ther 2007;320:499–506.
   PubMed Web of Science ®Google Scholar
• Jung SK, Hong MS, Suh GJ, Jin SY, Lee HJ, Kim BS, et al. Association between polymorphism in intron 1 of cocaine- and amphetamine-regulated transcript gene with alcoholism, but not with bipolar disorder and schizophrenia in Korean population. Neurosci Lett 2004;365:54–57.
   PubMed Web of Science ®Google Scholar
• First M, Spitzer R, Gibbon M, JBW W. Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometrics Research Department, New York State Psychiatric Institute, Department of Psychiatry, Columbia University; 1995.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573–583.
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Brit J Psychiatry 1978;133:429–435.
   PubMed Web of Science ®Google Scholar
• Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 1996;53:777–784.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend 1996;42:49–54.
   PubMed Web of Science ®Google Scholar
• Robinson SM, Sobell LC, Sobell MB, Leo GI. Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. J Soc Psychol Addict Behav 2014;28:154–162.
   PubMed Web of Science ®Google Scholar
• Zhang G, Qin L, Shi Y. Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J Bone Miner Res 2007;22:1072–1079.
   PubMed Web of Science ®Google Scholar
• Cohen J. A power primer. Psychol Bull 1992;112:155–159.
   PubMed Web of Science ®Google Scholar
• Brown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety 2006;23:492–495.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Carmody T, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9:4559.
   Google Scholar